Loading stock data…
Abeona Therapeutics Inc (ABEO)
$5.83-0.17 (-2.83%)
Market OpenUpdated 9:34 AM EDT
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Abeona Therapeutics Inc. in the Healthcare sector is trading at $5.85 with a market capitalization of $327M. Wall Street consensus targets $18.86 (7 analysts), implying a +222.3% move over the next 12 months. The stock is currently 24% below its 52-week high of $7.65, remaining 6.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +222.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.72M↑ | $5.42M | $0↓ | $400,000 | $0 |
| Gross Profit | $6.02M↑ | $2.58M↑ | -$488,000↓ | $300,000 | $0 |
| Operating Income | -$23.03M↓ | -$22.91M↑ | -$24.02M↓ | -$22.79M↓ | -$19.73M |
| Net Income | -$17.07M↑ | -$20.46M↓ | -$5.16M↓ | $108.83M↑ | -$12.03M |
Peer Comparison
JNJUNHPFE
Fundamentals
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$327.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
45.63%
Volume
Today's trading volume
22,850
Recent News
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone
On August 13, Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter results that captured a company scaling a genuinely new kind of medicine while working through the bumps that come with it. ZEVASKYN, its cell therapy for a severe skin disease called recessive dystrophic epidermolysis bullosa, brought in $11.4 million in revenue for the quarter, and the number […]
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...
Despite manufacturing hiccups and patient cancellations, the company expands its treatment center network and secures CMS NTAP status to bolster market access.
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby summary of Abeona Therapeutics Inc.'s Q2 2026 earnings call
Abeona Therapeutics Q2 Earnings Call Highlights
Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that affected revenue recognition. The company recorded net ZEVASKYN revenue of $11.4 million for the
Insider Favorites: Top Growth Companies For June 2026
Over the last 7 days, the United States market has experienced a 3.3% drop, yet it remains up by 22% over the past year with earnings expected to grow by 17% annually. In this context, identifying growth companies with high insider ownership can be particularly appealing as it often indicates strong confidence from those closest to the business in its future potential.